Editas Medicine, Inc. (NASDAQ:EDIT) insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $24.78, for a total transaction of $206,491.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Katrine Bosley also recently made the following trade(s):

  • On Friday, September 1st, Katrine Bosley sold 10,000 shares of Editas Medicine stock. The stock was sold at an average price of $20.42, for a total transaction of $204,200.00.
  • On Tuesday, September 5th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.33, for a total transaction of $338,819.78.
  • On Friday, August 11th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.02, for a total transaction of $333,653.32.

Editas Medicine, Inc. (EDIT) traded down 7.99% during trading on Wednesday, reaching $23.50. 2,263,786 shares of the company’s stock traded hands. Editas Medicine, Inc. has a 12 month low of $12.43 and a 12 month high of $28.50. The firm has a 50 day moving average price of $21.98 and a 200-day moving average price of $21.98. The firm’s market cap is $961.76 million.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The firm’s revenue for the quarter was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. On average, analysts forecast that Editas Medicine, Inc. will post ($2.88) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/editas-medicine-inc-edit-insider-sells-206491-74-in-stock.html.

Institutional investors have recently added to or reduced their stakes in the company. Paulson & CO. Inc. acquired a new position in shares of Editas Medicine during the 1st quarter worth about $1,116,000. UBS Group AG grew its stake in Editas Medicine by 747.7% in the 1st quarter. UBS Group AG now owns 78,217 shares of the company’s stock valued at $1,746,000 after buying an additional 68,990 shares during the last quarter. Driehaus Capital Management LLC grew its stake in Editas Medicine by 169.8% in the 1st quarter. Driehaus Capital Management LLC now owns 125,684 shares of the company’s stock valued at $2,805,000 after buying an additional 79,104 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in Editas Medicine in the 2nd quarter valued at about $1,322,000. Finally, Omega Advisors Inc. acquired a new position in Editas Medicine in the 1st quarter valued at about $1,116,000. Institutional investors own 69.37% of the company’s stock.

EDIT has been the topic of several analyst reports. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Wednesday, July 12th. SunTrust Banks, Inc. initiated coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They set a “hold” rating and a $17.00 target price on the stock. Cann initiated coverage on shares of Editas Medicine in a research report on Monday, July 17th. They set a “market perform” rating on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Finally, J P Morgan Chase & Co set a $27.00 target price on shares of Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Six analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $25.52.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.